Baird Medical Secures Regulatory Approvals in Pakistan and Vietnam
Rhea-AI Summary
Baird Medical (NASDAQ: BDMD) announced on January 7, 2026 that it received official product registrations from the Medical Device Board of Pakistan and the Ministry of Health of Vietnam. The company executed a Pakistan product launch at the Armed Forces Institute of Radiology & Imaging (AFIRI) under the professional guidance of Dr. Raza Raheem.
Vietnam registration expands Baird Medical's compliant footprint in Southeast Asia and supports its stated global commercialization strategy by enabling market entry and clinician access to its microwave ablation (MWA) technology.
Positive
- Regulatory approvals secured in Pakistan and Vietnam on January 7, 2026
- Official product launch completed at AFIRI in Pakistan
- Vietnam approval expands compliant footprint in Southeast Asia
Negative
- None.
News Market Reaction – BDMD
On the day this news was published, BDMD gained 3.88%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Medical Devices showed mixed moves: ICAD up 3.48%, ICCM up 1.4%, while NSPR fell 5.73% and XTNT slipped 1.11%. This dispersion suggests BDMD’s regulatory approvals are more company-specific than part of a uniform sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Manufacturing expansion | Positive | +2.2% | Established U.S. manufacturing base via partnership with MPS Medical. |
| Dec 08 | Clinical training | Positive | -4.9% | Advanced MWA training for Arizona surgeon with live procedures. |
| Dec 03 | Leadership change | Positive | +11.1% | Appointed veteran medical-device executive as U.S. CEO. |
| Nov 03 | Market entry | Positive | -9.2% | First successful bone tumor ablation marking Egyptian market entry. |
| Oct 27 | Reimbursement milestone | Positive | +2.1% | MWA system procedures at NY practice successfully reimbursed by Medicare. |
Recent company news has generally been positive operationally, but market reactions have been mixed, with both rallies and selloffs following expansion and adoption milestones.
Over the last few months, Baird Medical reported several expansion and adoption milestones. On Oct. 27, 2025, its MWA system achieved Medicare reimbursement at a New York practice, with a 2.14% price gain. Entry into Egypt with a first bone tumor ablation on Nov. 3, 2025 saw a -9.16% move. Appointment of a U.S. CEO on Dec. 3, 2025 coincided with an 11.11% rise. Subsequent U.S. training and manufacturing-base news in December drew smaller, mixed reactions, showing no consistent pattern despite strategic progress.
Market Pulse Summary
This announcement highlights Baird Medical’s continued international expansion, adding regulatory approvals and product registration in Pakistan and Vietnam to earlier moves into Egypt, Indonesia, Malaysia, and key U.S. practices. These updates extend the reach of its microwave ablation platform under recognized health authorities. Recent history shows progress in reimbursement, leadership, and manufacturing capacity. Investors may focus on procedure volumes, further regulatory clearances, and adoption trends to gauge how these milestones translate into sustainable commercial growth.
Key Terms
microwave ablation (mwa) medical
ministry of health regulatory
interventional radiology medical
minimally invasive medical
AI-generated analysis. Not financial advice.
In
Simultaneously, the registration approval in
"Securing these approvals in
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the
The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-secures-regulatory-approvals-in-pakistan-and-vietnam-302654738.html
SOURCE BDMD
FAQ
What approvals did Baird Medical (BDMD) announce on January 7, 2026?
How does the Pakistan product launch affect BDMD's commercialization timeline?
Does the Vietnam registration allow Baird Medical (BDMD) to sell products in Southeast Asia?
Who guided the Pakistan launch for Baird Medical (BDMD)?
What technology did Baird Medical (BDMD) highlight in the Jan 7, 2026 announcement?
Will the approvals announced by BDMD on January 7, 2026 likely affect global expansion?
